Illness and Prevention and Allergy Studies with Relevance to Naväge
Illness/Prevention and Allergy Studies with Relevance to Naväge Overview:
The RINSI Study —Peer-reviewed clinical trial in which Naväge is named as a device, giving the brand a direct and ownable connection to the science that no competitor can claim.
The ELVIS Study — The mechanism proof, confirming not only that nasal irrigation works but that physical rinsing delivers results that passive sprays and gravity-based devices cannot replicate.
The Allergic Rhinitis Meta-Analysis — The strongest clinical backing for Naväge's allergy positioning, with a 62% reduction in allergy medication use across 10 randomized controlled trials.
The Lancet Study — The largest and most timely category-level validation of nasal irrigation available, currently driving the biggest wave of mainstream media coverage the space has ever seen (featured in WIRED).
THE RINSI STUDY Augusta University | Published: Ear, Nose and Throat Journal, 2022
What it was A peer-reviewed randomized clinical trial testing whether starting nasal irrigation within 24 hours of a positive COVID-19 test reduced hospitalization and death in high-risk patients aged 55 and older. Naväge was one of two devices used in the trial (NeilMed Sinus Rinse was also named in the study).
What it found Participants who initiated nasal irrigation were 8 times less likely to be hospitalized than the national CDC rate.
Why it matters beyond COVID The researchers themselves stated that nasal irrigation under pressure has been demonstrated to reduce the duration and severity of both coronaviruses and illnesses like flu. The mechanism is not COVID-specific. The nose is the entry point for virtually every respiratory virus. Flushing viral particles out before they replicate and reach the lungs reduces severity regardless of which virus is present.
Naväge's unique position Naväge is one of only two nasal irrigation brands named in the peer-reviewed clinical research producing these findings, and the only powered suction device in the trial.
THE ELVIS STUDY University of Edinburgh | Published: Scientific Reports, January 2019
What it was A randomized controlled trial by Ramalingam, Graham, Dove, Morrice and Sheikh testing hypertonic saline nasal irrigation and gargling against standard care in 68 adults with upper respiratory tract infections, started within 48 hours of symptom onset.
What it found Participants who rinsed saw:
illness duration reduced by 1.9 days,
over-the-counter medication use reduced by 36%,
transmission to household contacts reduced by 35%,
and viral shedding reduced measurably.
93% of participants said nasal irrigation made a difference to their symptoms. PubMed
The study specifically noted that alternatives such as nasal sprays are options, but they would not have the physical rinsing component of nasal irrigation. Nature This directly validates why Naväge's powered suction approach matters more than a simple spray.
Why it matters beyond the common cold Post-hoc analysis from this study found that hypertonic saline nasal irrigation reduced the duration of coronavirus upper respiratory tract infections by an average of two and a half days. PubMed Central The same researchers later called for nasal irrigation to be considered as a treatment option across respiratory viruses broadly, including flu, RSV, and coxsackievirus.
THE ALLERGIC RHINITIS META-ANALYSIS Published: American Journal of Rhinology and Allergy, 2012
What it was A systematic review and meta-analysis by Hermelingmeier et al. examining 10 randomized controlled trials involving over 400 participants, evaluating the impact of saline nasal irrigation as an adjunctive treatment for allergic rhinitis across adults and children.
What it found Saline nasal irrigation produced a
27.66% improvement in nasal symptoms,
62.1% reduction in medicine consumption,
31.19% acceleration of mucociliary clearance,
and a 27.88% improvement in quality of life.
It was found to be well tolerated, inexpensive, and easy to use with no evidence of adverse health effects. PubMed Central
Why it matters for Naväge The 62% reduction in allergy medication use is the single most compelling stat for Naväge's allergy positioning. It directly supports the core claim that nasal irrigation removes the cause rather than just treating symptoms, and that doing so consistently reduces dependence on antihistamines and other allergy drugs. This is not a prevention study in the traditional sense but it is arguably the most directly relevant study to how most Naväge users experience allergy season.
A note on scope This study covers allergic rhinitis specifically, not sickness prevention. It is best used in allergy-focused content and campaigns rather than cold and flu messaging. Paired with the RINSI and ELVIS studies, it completes a three-study picture: nasal irrigation reduces illness duration, reduces hospitalization risk, and reduces allergy medication dependence.
THE LANCET RESPIRATORY MEDICINE STUDY University of Southampton | Published: Lancet Respiratory Medicine, August 2024
What it was A large-scale randomized controlled trial across 332 GP practices in the UK testing whether nasal sprays or behavioral interventions reduced the duration of acute respiratory illness compared to standard care. More than 11,000 participants took part, making it one of the largest studies of its kind on nasal irrigation and respiratory illness.
What it found Nasal saline irrigation, started at the first sign of symptoms and performed up to six times per day, reduced the duration of symptomatic illness by approximately two days.
Why it matters for Naväge This study covers everyday acute respiratory illness, the kind that affects people three times a year on average. It validates the core principle behind Naväge: flush early, flush consistently, get better faster. It is also the study currently generating mainstream media coverage, including WIRED, Katie Couric Media, CBS, NBC, and ABC affiliates nationwide within the last week, making it an active and credible news peg